# Communicating medication risks in pregnancy: Towards shared decision making

## TL;DR

This paper discusses how better communication about medication risks during pregnancy can improve decision-making and health outcomes.

## Contribution

The paper introduces the Swiss MAMA-MEDS initiative as a model for unified, evidence-based communication resources.

## Key findings

- Current medication risk communication in pregnancy is fragmented and often emphasizes harms.
- Integrated resources can reduce misinformation and improve adherence to essential treatments.
- The MAMA-MEDS initiative supports patient-centered care and addresses health inequalities.

## Abstract

Medication use during pregnancy is common, yet safety data remain limited, often leading to exaggerated risk perceptions and suboptimal care. Current communication practices are fragmented: product labeling and patient leaflets tend to emphasize potential harms, while specialized resources are underused. We explore the challenges of conveying accurate risk-benefit information and highlight the need for shared decision making. Integrated, evidence-based resources accessible to both healthcare providers and patients can reduce misinformation, improve adherence to essential treatments, and ultimately enhance maternal and child health. The Swiss MAMA-MEDS initiative illustrates how a unified knowledge base can align messaging, address health inequalities, and support patient-centered pregnancy care.